Highlights • This study revealed that cells with high LIM scores were predominantly fibroblasts.• A risk model constructed from nine LIM domain family signature genes (CRYAB, RGS16, CSRP2, RCAN2, TPM1, EGFL7, PLS3, PDGFRA, and PLAU) accurately predicted the prognosis of CRC patients.• Erlotinib, fulvestrant, EPZ5676, and AZD1208 were identified as potential therapeutic agents for patients in the low-LIMRS group, whereas vinblastine, docetaxel, paclitaxel, and vinorelbine may be more suitable for high-LIMRS group patients.
Xinyu Zhao, Yili Shao, Huang Huang et al.· Translational Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.